The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
An article from
IPO window
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
Published July 15, 2026
Getty Images
Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately…
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during…
Attovia files for a Nasdaq IPO under ticker ATTO, becoming the third biotech to file this month after Scribe and Apnimed.
Braveheart Bio files for a $318.8M IPO on Nasdaq backed by a16z Bio + Health, targeting a $1.2B valuation for its heart drug…
Braveheart Bio files for a $319M Nasdaq IPO backed by a16z Bio + Health, raising questions about how crypto's biggest VC…
